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Abstract: In dogs, symmetrical lupoid onychodystrophy (SLO) results in nail loss and an abnormal
regrowth of the claws. In Bearded Collies, an autoimmune nature has been suggested because certain
dog leukocyte antigen (DLA) class II haplotypes are associated with the condition. A genome-wide
association study of the Bearded Collie revealed two regions of association that conferred risk for
disease: one on canine chromosome (CFA) 12 that encompasses the DLA genes, and one on CFA17.
Case-control association was employed on whole genome sequencing data to uncover putative
causative variants in SLO within the CFA12 and CFA17 associated regions. Genotype imputation was
then employed to refine variants of interest. Although no SLO-associated protein-coding variants
were identified on CFA17, multiple variants, many with predicted damaging effects, were identified
within potential candidate genes on CFA12. Furthermore, many potentially damaging alleles were
fully correlated with the presence of DLA class II risk haplotypes for SLO, suggesting that the
variants may reflect DLA class II haplotype association with disease or vice versa. Strong linkage
disequilibrium in the region precluded the ability to isolate and assess the individual or combined
effect of variants on disease development. Nonetheless, all were predictive of risk for SLO and, with
judicious assessment, their application in selective breeding may prove useful to reduce the incidence
of SLO in the breed.
Keywords: SLO; onychodystrophy; onychomadesis; dogs; autoimmune; DLA; MHC; WGS;
genomics; imputation
1. Introduction
Symmetrical lupoid onychodystrophy (SLO; OMIA 001989-9615) is a painful condi-
tion afflicting the nails of dogs. It is characterized by inflammation of the nail bed with
secondary bacterial infection that causes the claws to slough off. Regrowth of nails is
often abnormal, resulting in deformed and brittle claws in otherwise healthy dogs [1–4].
While uncommon in the overall dog population, a relatively higher prevalence of SLO has
been described in Bearded Collies [4,5], German Shepherds [6], and Gordon and English
Setters [7].
Disease etiology remains unclear, although an autoimmune component has been
suggested and supported by recent studies [3,8,9]. For example, certain major histocom-
patibility complex (MHC; or dog leukocyte antigen, DLA) class II haplotypes are more
frequently seen in Bearded Collies and Gordon Setters that have SLO [8–10], and are thus
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considered risk haplotypes for the disease. Genome-wide association studies (GWAS) for
SLO in both Bearded Collies and Gordon Setters have indicated a region of association on
canine chromosome (CFA) 12 that includes the DLA class II genes [3,11], further supporting
the involvement of the DLA genes in SLO disease development.
However, stretches of linkage disequilibrium (LD) ranging from 0.4 to 3.2 megabases
(Mb) long are known to exist within dog breeds [12,13]. While this genomic structure
provides an advantage for studying genetic association with phenotypes in dogs, where
association mapping requires fewer markers than in humans [13], fine mapping of causative
variants can be more challenging. As in humans, the MHC region of the dog genome
exhibits particularly long stretches of strong LD [14], and numerous genes are found in
that genomic region of CFA12. It is therefore possible that the DLA association identified is
a result of LD rather than true causation. For example, in Bearded Collies, the strongest
association observed in the GWAS was seen with a single nucleotide polymorphism (SNP)
located in the intronic region of a tenascin gene (TNXB), and that TNXB GWAS SNP was
fully correlated with the presence of DLA class II risk haplotypes for SLO [11].
In Bearded Collies, a second region of association was also identified on CFA17.
Moreover, a stronger association of the CFA17 region was noted when only Bearded
Collies carrying DLA class II risk haplotypes were included in the GWAS. Despite its clear
association with SLO, no obvious additive effect of the CFA17 locus on the risk for disease
conferred by the CFA12 locus was noted. A potential candidate gene (regenerating family
member 3 alpha, REG3A) was identified adjacent to the associated region on CFA17. The
REG3A protein functions to modulate epidermal repair after skin injury by regulating
keratinocyte proliferation and differentiation [15]. A dog’s nail beds are under constant
mechanical stress and periods of intense training are thought to contribute to SLO disease
onset [3], thus making this gene a good candidate for SLO disease risk.
Many potential candidate genes, beyond the DLA, exist in the CFA12 region indicated
by the GWAS and a relatively small number are found in the CFA17 region. The purpose
of this study was to explore whole genome sequencing (WGS) data from SLO-affected
and healthy Bearded Collies in order to identify putative causative variants within the
two GWAS-associated regions on CFA12 and CFA17. To refine the large number of WGS
variants observed in the regions of interest, genotype imputation, which has been shown
to accurately predict WGS genotypes based on data from high-density SNP arrays [16–18],
was also employed.
2. Materials and Methods
2.1. Samples
Whole blood samples were obtained from SLO and healthy Bearded Collies. Dogs
included as SLO cases had been diagnosed by a veterinarian based on clinical signs,
including brittle nails, inflamed nail bed, nail bleeding, single or multiple nail loss with
subsequent abnormal nail growth, and exclusion of other potential causes of nail loss;
three SLO dogs also had a biopsy of the nail beds showing signs consistent with SLO.
Dogs selected as healthy controls were clinically healthy and at least 10 years old, with no
history of nail abnormalities or immune-related disorders, diagnosed or suspected. DNA
was extracted from blood samples, as previously described [19], and quantified using a
Nanodrop® spectrophotometer and Qubit® fluorometer.
2.2. WGS and Variant Calling
DNA aliquots from 26 Bearded Collies (7 with SLO, 8 healthy controls above 10 years,
and 11 Bearded Collies that were free from SLO and sequenced for other studies) were
submitted to Novogene (Novogene, Beijing, China) for WGS. The SLO dogs (3 females,
4 males) and healthy control dogs (2 females, 6 males) were unrelated up to the grand-
parent level, except for one SLO and one control dog that shared a grandsire. The SLO
dogs included the three cases with nail bed biopsies. Age at SLO diagnosis ranged from
20 months to 7 years (average age, 4.5 years), consistent with the literature [4,20]. Healthy
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control dogs were from 11 to 15 years old (median age 12.5 years). The Illumina HiSeq X™
Ten platform was used to sequence a PCR-free library with fragment sizes of approximately
350 bp to obtain 150 bp paired-end reads and an average of 15× coverage. Raw sequence
data files were processed according to the Broad Institute’s Genome Analysis Tool Kit
(GATK) best practices workflow for small germline variants [21]. Briefly, FastQC [22] was
used to check the quality of the raw reads, which were then subjected to quality-based
trimming with Trimmomatic version 0.39 [23]. Trimmed reads were aligned to the CanFam
3.1 reference genome available on Ensembl [24] using BWA-MEM version 0.7.16a [25].
Some samples had been run on more than one sequencing lane so that each of those dogs
contained 2–3 mapped files. For those samples, Samtools version 1.9 [26] was used to sort
and index each mapped file and Picard-tools version 2.23.4 [27] was used to merge the
files into a single combined mapped file per sample. In preparation for variant calling,
Picard-tools was also used to mark duplicate reads and GATK version 4.2.0.0 was used
for base recalibration. GATK’s HaplotypeCaller was then used to call variants in each
individual sample, followed by joint variant calling across all samples. Variant files were
then annotated with SnpEff version 5.0e [28] using the CanFam3.1 reference genome, and
Ensembl annotation version 104 was used to add information about the location of each
variant relative to the genes and the effect of those variants on resulting proteins (i.e.,
synonymous, missense, frameshift, etc.).
2.3. Variant Filtering for Case-Control Association on 7 SLO and 8 Healthy Controls
Given that haplotype blocks significantly associated with SLO had been identified
in CFA12 between 1.2 Mb and 6.5 Mb [11], variants called within the first 7.5 Mb of
CFA12 were extracted from the main WGS dataset for the 7 SLO and 8 healthy controls
for further analysis; similarly, variants located between 44 and 47 Mb of CFA17 were also
extracted. These ranges allowed for approximately 1 Mb flanking region on each side of the
GWAS SLO-associated regions. Individual call rates within the regions of association were
calculated using PLINK version 1.9 [29]; samples with less than 90% call rate were excluded
from further analysis. Variant files were filtered using VCFtools version 0.1.17 [30], keeping
variants called in at least 70% of dogs (i.e., 11 of 15 dogs), having a minor allele frequency
(MAF) greater than 5%, and supported by at least 3 reads. Additionally, variant files for
controls were filtered in PLINK to remove any variants that deviated from the Hardy–
Weinberg equilibrium (HWE) at p-value < 0.00005. Case-control p-values were calculated
for each of the remaining variants using SnpSift, a tool that uses 2 × 2 contingency tables to
count the number of non-reference genotypes in the case and control groups and uses the
Fisher exact test to calculate allelic p-values for each variant [31,32]. Variants with an allelic
case-control p-value < 0.05 and SnpEff-predicted high or moderate impact (Supplemental
Table S1) were then selected for further investigation.
2.4. Imputation
Genotype imputation was employed in an effort to refine the variants of interest in the
associated regions of CFA12 and CFA17. A reference panel for imputation was generated
from two datasets: our laboratory’s variant dataset obtained from WGS of 26 Bearded
Collies and a publicly available phased dataset obtained from WGS of 365 canids [16]. Both
datasets were processed according to GATK’s best practices workflow. Variants located
within the first 7.5 Mb of CFA12 were extracted from each of the datasets using VCFtools;
the same was performed for variants located between 44 and 47 Mb of CFA17 (Figure 1).
Individual call rates calculated by PLINK for the 26 Bearded Collies prior to filtering ranged
from 93.3% to 96.3% for CFA12 and from 94.9% to 97.3% for CFA17; thus, no samples were
excluded. To reduce the number of unreliable variants and genotype calls while preserving
as much genetic variability intrinsic to Bearded Collies as possible, filtering was applied to
the Bearded Collie datasets using VCFtools so that variants with less than a 70% call rate
across all individuals and genotypes supported by fewer than 3 reads were discarded. No
MAF or HWE filtering was performed when creating the reference panel for imputation,
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given that disease variants are expected to be present at low frequencies in the population
and any deviation from HWE could be an indication of genetic disease association, which
is why HWE filtering should only be applied to known controls in case-control studies [33].
Genotype phasing was performed using Beagle version 5.1 [34] and default parameters [35],
but adjusting the effective population size (Ne) to 24. Since the datasets consisted only
of Bearded Collies, and a 2015 UK study reported an Ne of 23.91 for the breed [36], an
effective population size of 24 was deemed appropriate. Bcftools [26] version 1.2 was used
to merge the CFA12 and CFA17 Bearded Collie subset datasets to the corresponding subsets
of the publicly available dataset. Beagle 5.1 was then used to phase the genotypes in the
merged datasets using default parameters, but this time adjusting Ne to 200, as described
in a previously published imputation study of a multibreed dataset [17]. Additionally,
the publicly available average CFA12 and CFA17 genetic maps [37] were used as input
for phasing. Finally, the datasets to be used as reference panels for imputation contained
391 samples and 111,740 variants for CFA12, and 391 samples and 20,854 variants for
CFA17. Among the 391 samples, 236 were dogs belonging to 77 breeds, 26 of which were
Bearded Collies; 107 were village dogs; and 28 were wolves [16]. The target dataset was
generated using genotype data from 82 unrelated Bearded Collies (30 SLO and 52 healthy)
included in a previous GWAS [11]. Genotypes for the Illumina Canine HD BeadChip
SNPs located within the first 7.5 Mb of CFA12 and SNPs located between 44 and 47 Mb
of CFA17 were extracted and used to impute up to the 111,740 and 20,854 WGS variants,
respectively. The locations of the Illumina SNPs were based on the CanFam3.1 reference
genome available on Ensembl. PLINK version 1.9 [29] was used to subset the genotype
dataset and convert the files into VCF format. SNPs and individuals with less than 95% call
rate were removed from the dataset as well as SNPs deviating from HWE at p < 0.00005 in
the controls. Illumina SNPs with missing non-reference alleles after VCF conversion were
also removed (N = 32 for CFA12 and N = 11 for CFA17). After filtering, the CFA12 target
dataset contained 524 SNPs with a 98.7% call rate across the 82 unrelated dogs; the CFA17
contained 210 SNPs with a 99.8% call rate across samples. Beagle 5.1 was used to phase the
genotypes without imputing missing calls and an Ne of 24 was used for phasing. Conform-
gt [38] was then used to check for strand concordance between the target datasets and the
CFA12 and CFA17 reference panels, and variants found to be strand concordant (N = 516
and N = 182, respectively) were used for imputation. Beagle 5.1 was used to impute
genotypes [34,39] using the newly generated CFA12 and CFA17 reference panels and an Ne
of 24. The imputed VCF files were annotated using SnpEff [28], and SnpSift [31] was used
for a case-control analysis of each variant; the case-control analysis included the 82 dogs
from the GWAS [11]. Variants were then filtered based on allelic case-control p-value < 0.05
using SnpSift and compared to the variants of interest identified in the WGS data. Novel
variants of interest (i.e., variants not matching a previously known dbSNP record) were
checked through a manual inspection of mapped reads using the Integrative Genomics
Viewer (IGV) [40] to confirm variant calls prior to further investigation. Confirmed variants
of interest were then checked for variant effect using the Protein Variation Effect Analyzer
(Provean) online tool [41], which accepts any species for analysis and has been validated to
predict the effect of amino acid substitutions and inframe insertions or deletions (indels)
on the biological function of a protein [42]. Genomic Evolutionary Rate Profiling (GERP)
scores [43], based on the alignment of 90 mammalian species, were obtained from Ensembl
for each variant and used to assess the conservation of the particular amino acid across
mammals. The VassarStats online tool [44] was used to calculate the odds ratio (OR)
and the two-tailed Fisher’s exact p-values of the variants of interest supported by the
82 unrelated Bearded Collies through 2 × 2 contingency tables. Calculations were based
on the number of cases and controls that carried a particular genotype versus the number
of cases and controls not carrying that genotype. Statistically significant observations were
considered at p-value < 0.05. A VCF file containing the 11 variants of interest was recoded
into binary files in PLINK, and pairwise LD statistics were then calculated and plotted
using the genetic data handling package “gaston” version 1.5.7 [45] implemented in R [46].
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2.6. T XB Sequencing
Based upon the previous GWAS association [11], where the most significant SNP
was intronic to TNXB, 73 Bearded Collies from our database (35 SLO, 38 healthy controls)
were selected and genotyped for three missense variants in TNXB identified by WGS,
which were predicted to be deleterious by Provean [42]. Thirty-two of these 73 dogs
(20 SLO and 12 controls) had been included in the previous GWAS analysis; other dogs
that had been assessed in the GWAS could not be used for the TNXB sequencing be-
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cause their DNA was no longer available. Primers flanking each of the three SNPs were
designed using Primer 3 [47] (TNXB_925-F:CTTGTATTGGACCACGAAGGAG, TNXB_925-
R:TTCTATGCTCCAAGCTCCAAAG; TNXB_337-F:GGAGGCCCATGAAGCACA, TNXB_337-
R:CTGCCCATCCCCATTCTTGT; TNXB_360-F:GGCCTCTTTCTCTCACGTCC, TNXB_360-
R:CCCGTCTTCATGCCCTGG). A standard 33-cycle polymerase chain reaction (PCR)
protocol was used to amplify each product using Promega GoTaq® Flexi DNA Polymerase
(Promega, Madison, WI, USA) in a 25 µL reaction. A 62 ◦C annealing temperature was
used for the TNXB_925 primer set and 60 ◦C for the TNXB_337 and TNXB_360 primer sets.
Amplicon size was checked through gel electrophoresis, using 5 µL of the PCR product
run on a 1% agarose gel. Exosap-IT™ express (Thermo Fisher Scientific, Waltham, MA,
USA) was used to purify the PCR products, and sequencing was performed by capillary
electrophoresis on an ABI 3730 DNA analyzer (Applied Biosystems, Foster City, CA, USA).
Sequences were read with FinchTV v.1.4 (Geospiza, CO, USA) and aligned against the




The mapping of WGS data from the 26 Bearded Collies to the CanFam3.1 reference
genome resulted in an average genome-wide coverage of 15.6× per sample, with individual
dogs ranging from 11 to 20× coverage. After extracting variant data for the 15 Bearded
Collies (7 SLO, 8 healthy controls) for SLO analysis, 52,101 variants were present within
the first 7.5 Mb of CFA12 and 20,310 variants were present between 44 and 47 Mb of
CFA17. The individual call rate for the 15 Bearded Collies ranged from 93.4% to 96.5% on
CFA12 and from 95.5% to 97.6% on CFA17 prior to filtering. Of the variants called within
the CFA12 and CFA17 associated regions, 33,713 and 14,405 variants, respectively, were
supported by at least 3 reads, called in at least 70% of the dogs, and presented with an MAF
greater than 5%. Individual call rate after filtering ranged from 95.2% to 99% for CFA12 and
from 96.0% to 98.6% for CFA17. Variants were then filtered based on an allelic case-control
p-value < 0.05, leaving 5,607 variants for analysis on CFA12 (Figure 2). More importantly,
all variants in the associated region on CFA17 were eliminated. Of the 5607 variants on
CFA12, 8 were predicted to have a high impact and 59 were predicted to have a moderate
impact, as defined by SnpEff; 49 of those having moderate or high predicted impact were
present in at least 5 of the WGS SLO cases. One variant was excluded as a false call based
on the manual inspection of mapped reads.
Genes 2021, 12, x FOR PEER REVIEW 6 of 16 
 
 
were predicted to be deleterious by Provean [40]. Thirty-two of these 73 dogs (20 SLO and 
12 controls) had been included in the previous GWAS analysis; other dogs that had been 
assessed in the GWAS could not be used for the TNXB sequencing because their DNA 
was no longer available. Primers flanking each of the three SNPs were designed using 
Primer 3 [45] (TNXB_925-F:CTTGTATTGGACCACGAAGGAG, TNXB_925-R:TTC-
TATGCTCCAAGCTCCAAAG; TNXB_337-F:GGAGGCCCATGAAGCACA, TNXB_337-
R:CTGCCCATCCCCATTCTTGT; TNXB_360-F:GGCCTCTTTCTCTCACGTCC, 
TNXB_360-R:CCCGTCTTCATGCCCTGG). A standard 33-cycle polymerase chain reac-
tion (PCR) protocol was used to amplify each product using Promega GoTaq® Flexi DNA 
Polymerase (Promega, Madison, WI, USA) in a 25 µL reaction. A 62 °C annealing temper-
ature was used for the TNXB_925 primer set and 60 °C for the TNXB_337 and TNXB_360 
primer sets. Amplicon size was checked through gel electrophoresis, using 5 µL of the 
PCR product run on a 1% agarose gel. Exosap-IT™ express (Thermo Fisher Scientific, Wal-
tham, MA, USA) was used to purify the PCR products, and sequencing was performed 
by capillary electrophoresis on an ABI 3730 DNA analyzer (Applied Biosystems, Foster 
City, CA, USA). Sequences were read with FinchTV v.1.4 (Geospiza, CO, USA) and 
aligned against the CanFam3.1 reference sequence using CLC viewer v.7.8.1 (QIAGEN 
Bioinformatics, Aarhus, Denmark) for genotyping. 
3. Results 
3.1. WGS 
The mapping of WGS data from the 26 Bearded Collies to the CanFam3.1 reference 
genome resulted in an average geno e-wide coverage of 15.6× per sample, with individ-
ual dogs ranging from 11 to 20× coverage. After extracting variant data for the 15 Bearded 
Collies (7 SLO, 8 healthy controls) for SLO analysis, 52,101 variants were present within 
the first 7.5 Mb of CFA12 and 20,310 variants were present between 44 and 47 Mb of 
CFA17. The individual call rate for the 15 Bearded Collies ranged from 93.4% to 96.5% on 
CFA12 and from 95.5% to 97.6% on CFA17 prior to filtering. Of the variants called within 
the CFA12 and CFA17 associated regions, 33,713 and 14,405 variants, respectively, were 
supported by at least 3 reads, called in at least 70% of the dogs, and presented with an 
MAF greater than 5%. Individual call rate after filtering ranged from 95.2% to 99% for 
CFA12 and from 96.0% to 98.6% for CFA17. Variants were then filtered based on an allelic 
case-control p-value < 0.05, leaving 5,607 variants for analysis on CFA12 (Figure 2). More 
importantly, all variants in the associated region on CFA17 were eliminated. Of the 5,607 
variants on CFA12, 8 were predicted to have a high impact and 59 were predicted to have 
a moderate impact, as defined by SnpEff; 49 of those having moderate or high predicted 
impact were present in at least 5 of the WGS SLO cases. One variant was excluded as a 
false call based on the manual inspection of mapped reads.  
 
Figure 2. Filtering process of whole genome sequence variants identified within the GWAS regions of association on canine
chromosomes (CFA) 12 and 17 for further exploration of their association with symmetrical lupoid onychodystrophy (SLO)
in Bearded Collies. Chromosome locations are based on the CanFam3.1 reference genome. Software used in each step
indicated in parenthesis.
Genes 2021, 12, 1265 7 of 15
3.2. Variants from Imputed Dataset
Genotype imputation of WGS variants was employed on the 82 unrelated Bearded
Collies included in the previous GWAS in an effort to refine the list of variants for fur-
ther exploration. Imputation accuracy, estimated as the percentage of correctly imputed
genotypes in 24 Bearded Collies, averaged 91.7% for SNPs (range 81.3–98.3%) and 87.6%
for insertions or deletions (i.e., indels; range 78.5–97.8%) on CFA12, and 86.8% for SNPs
(range 75.1–99.4%) and 84.6% for indels (range 73.0–98.9%) on CFA17, similar to what has
previously been achieved with a multi-breed reference panel [16–18].
Of the 48 variants identified in the CFA12 WGS data, 43 were present in at least
25 of 30 unrelated cases and remained significantly associated with SLO in the imputed
dataset (i.e., case-control allelic p-value < 0.05; Supplementary Table S2). The effect of 32
of those 43 variants on the resulting protein was predicted to be neutral by Provean, thus
eliminating them from further analysis. The remaining 11 variants of interest consisted of
7 missense mutations, 3 frameshift variants, and 1 splice acceptor variant (Table 1). The
missense variants were predicted to be deleterious by Provean, including the three found
in TNXB. Though Provean is not currently able to ascribe a consequence to frameshift and
splice acceptor variants, they can have damaging consequences on the resulting protein:
frameshift variants can change the reading frame beginning at the site of insertion/deletion
and can lead to several amino acids being changed in the protein or even a premature stop
codon [48], whereas splice acceptor variants can impair proper gene splicing [49].
Table 1. Variants of interest selected for further exploration on canine chromosome (CFA) 12. Odds ratio (OR) calculated for




Rs Number * Gene
All Tran-
scripts Affected? Variant Type
GERP Conserva-
tion Score §
SLO (N = 30) Controls (N = 52)




815793 rs851051888 C12H6orf15 Yes Missense 0.16 26 4 18 25 12.3 (3.7–40.7) 0.000007
840504 rs851625125 ENSCAFG00000041540 Yes
Splice
acceptor −0.15 26 4 18 25 12.3 (3.7–40.7) 0.000007
854936 Novel TCF19 Yes Frameshift NA 26 4 18 25 12.3 (3.7–40.7) 0.000007
855098 Novel TCF19 Yes Frameshift NA 26 4 18 25 12.3 (3.7–40.7) 0.000007
1080999 rs852946032 LTB Yes Missense 0.16 26 4 32 15 4.1 (1.2–13.4) 0.022579
1459925 rs22185869 TNXB Yes Missense −0.86 26 4 17 25 13.4 (4.0–44.5) 0.000002
1469337 rs8493203 TNXB Yes Missense −4.06 26 4 17 25 13.4 (4.0–44.5) 0.000002
1476360 rs853176058 TNXB Yes Missense 2.66 26 4 17 25 13.4 (4.0–44.5) 0.000002
1585012 rs851873877 GPSM3 No Frameshift 0.16 26 4 17 25 13.4 (4.0–44.5) 0.000002
2248914 rs851008370 HLA-DQB2 No Missense 0.16 26 4 32 15 4.1 (1.2–13.4) 0.022579
6077432 rs852291453 FGD2 No Missense 0.41 17 13 12 18 4.4 (1.7–11.5) 0.003677
* Previously reported variant identification number obtained from Ensembl; § Genomic Evolutionary Rate Profiling score based on the align-
ment of 90 mammalian species; ¶ Two-tailed Fisher’s Exact p-value; CI—confidence interval; SLO—symmetrical lupoid onychodystrophy;
HO ALT—homozygous non-reference genotype; HET—heterozygous genotype.
The homozygous reference genotype was completely absent from the SLO group at all
11 variants of interest (Figure 3), and almost all SLO dogs (87%) presented a homozygous
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3.3. TNXB Sequencing
Given that the top genome-wide significant SNP from the GWAS was intronic to TNXB,
a gene that encodes an extracellular matrix protein that is ubiquitously expressed in the
skin, and provided that the majority of SLO dogs was homozygous for the non-reference
allele at all three missense variants predicted to have deleterious effects on the resulting
protein, highest priority was given to investigating these variants in additional dogs.
Of the variants observed in TNXB, 11 were missense variants with an allelic case-
control association p-value < 0.05. Three of those (rs22185869, rs8493203, and rs853176058)
were predicted by Provean to have deleterious consequences in all known transcripts. The
variants resulted in the substitution of a proline to a leucine, a proline to an arginine, and
an aspartic acid to a glycine, respectively. The first two variants displayed negative GERP
scores in Ensembl, indicating a high variability of amino acids in those positions across
mammalian species; however, the third variant (rs853176058) had the highest positive
GERP score of all variants of interest in Table 1, indicating high conservation across species
and suggesting that alterations at this site could impact protein function.
All seven WGS SLO dogs were homozygous for the non-reference allele at all three
TNXB SNPs, whereas two controls were homozygous and three were heterozygous for the
missense substitutions. Genotyping of 73 additional Bearded Collies (35 SLO and 38 healthy
controls) confirmed the association of the deleterious SNPs with SLO (Table 2). For an
additional evaluation of the quality of imputation, genotype concordance in the imputed
data was also checked for the three missense variants predicted to be deleterious in TNXB.
Thirty-two of the 73 Bearded Collies sequenced for TNXB were also included in the GWAS
and their imputed genotypes fully matched the genotypes obtained through sequencing.
Table 2. Genotypes at each of the three missense variants predicted to be deleterious in TNXB for Bearded Collies and the
type of DLA class II haplotypes (i.e., risk haplotype or non-risk haplotype for SLO) associated with those TNXB variant
combinations. Variant locations are based on the CanFam3.1 reference genome.




OR (95% CI) p-Value ¶ DLA Class II
Risk Haplotypes 112:1459925 12:1469337 12:1476360
GG GG TT 1 8 0.12 (0.01–0.97) 0.03139 No risk haplotypes
GA GC TC 5 23 0.14 (0.05–0.41) 0.00018 1 risk haplotype
AA CC CC 36 15 12.4 (4.29–35.85) 4.1 × 10−7 2 risk haplotypes
1 Risk haplotypes defined in [8]; ¶ Two-tailed Fisher’s Exact p-value; OR—odds ratio; CI—confidence interval; SLO—symmetrical lupoid
onychodystrophy.
Two DLA class II risk haplotypes have been previously associated with increased risk
for SLO in Bearded Collies [8,11]. Dogs that were homozygous for the non-reference allele
at all three TNXB SNPs also carried two DLA class II risk haplotypes for SLO (i.e., either
homozygous for one of the risk haplotypes or carrying one of each of the two DLA class II
risk haplotypes), whereas dogs that were heterozygous at all three SNPs carried one risk
and one non-risk DLA class II haplotype. Dogs that were homozygous reference at the
SNPs had no DLA class II risk haplotypes. More specifically, there was direct concordance
with the presence of the TNXB variants and that of the DLA class II haplotypes identified
as conferring risk.
3.4. Additional Variants on CFA12
The variants identified in the CFA12 associated region affected 8 genes, one of which
(ENSCAFG00000041540) is defined as a pseudogene in Ensembl. In addition to TNXB, four
genes (lymphotoxin B, LTB; G protein signaling modulator 3, GPSM3; major histocom-
patibility complex, class II, DQ beta 2, HLA-DQB2; and FYVE, RhoGEF and PH domain
containing 2, FGD2) could be considered potential candidate genes given their role in
the immune system. The variants in LTB and HLA-DQB2 had the lowest ORs, with the
non-reference and potentially deleterious allele being present in a homozygous state in
many control dogs. The second lowest OR was observed for the FGD2 variant, which
was the only variant of interest where the majority of SLO dogs were not homozygous for
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the variant. The GPSM3 variant, while promoting a frameshift at the very beginning of
the coding sequence that causes the resulting protein to be significantly shorter than the
wildtype, only affected one of three known transcripts. Although not clearly associated
with the immune system, of the remaining variants, those in the transcription factor 19 gene
(TCF19) affected all known transcripts and resulted in a premature stop codon and a smaller
resulting protein, which could indicate significant impairment of function.
Further sequencing of the TCF19, LTB, and GPSM3 variants in more dogs was con-
sidered. However, pairwise LD calculations demonstrated moderate to strong linkage
disequilibrium throughout the entire region (Figures 3 and 4), most especially between vari-
ants in TCF19, LTB, GPSM3, and TNXB, indicating that the observed deleterious variants
would all follow the same pattern of direct linkage with the DLA class II risk haplotypes,
as seen with the TNXB sequencing. Therefore, additional sequencing of these genes would
fail to resolve whether they or the DLA class II risk haplotypes were causal or correlated.
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3.5. CFA17
No variants of interest (with high or moderate impact) were identified on CFA17,
according to the criteria used to select variants for further investigation. Given that
a potential candidate gene was identified adjacent to the CFA17 region of association,
variants called within that gene were reviewed separately. Forty-two variants were called
in REG3A: one in the five prime untranslated region (UTR), four in the three prime UTR,
36 intronic, and one in the coding region of the gene, which was synonymous and predicted
to have low impact on the resulting protein. None of the variants in either UTR or intron 1
of REG3A presented with an allelic case-control p-value < 0.05 among the WGS dogs or the
82 unrelated dogs. Therefore, none of these variants were investigated further.
4. Discussion
The investigation of WGS data in an effort to define causal variants in SLO in Bearded
Collies revealed several potentially damaging variants within the risk-associated region
of CFA12 that were homozygous in the majority of SLO dogs. The variants on CFA12
affected 8 protein-coding genes, one defined as a pseudogene with no known orthologues
in Ensembl. The highest ORs associated with SLO disease status were observed for
three missense variants in TNXB, one of which is reported to be highly conserved across
mammalian species, and a frameshift variant in the adjacent GPSM3 gene. TNXB encodes
the extracellular matrix protein tenascin-X found extensively in the skin, including the
dermal papillae of the human nail matrix and hyponychium [50], where it organizes and
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maintains connective tissue structure [51]. A SNP in human TNXB has been associated
with systemic lupus erythematosus [52], although its role in autoimmunity remains unclear.
Combined with the top GWAS SNP for SLO being intronic to TNXB [11], the gene was
considered a potential candidate for SLO susceptibility. The three missense variants in
TNXB were predicted to be deleterious and were present at significantly greater frequency
in SLO dogs compared to controls. Two of the three missense variants, including that for
the highly conserved position, result in the substitution of a non-polar to polar amino acid
(proline to arginine and aspartic acid to glycine), which could affect the 3-dimensional
structure of the resulting protein.
Missense variants in TNXB have recently been implicated in skin hyperextensibility in
a mixed-breed dog, generating a phenotype reminiscent of Ehlers–Danlos syndrome. Those
two missense variants (c.2012G > A and c.2900G > A) were extremely rare in the overall
dog population and only seen in the heterozygous state [53]. Though indels or truncating
mutations are more commonly associated with Ehlers–Danlos syndrome, missense variants
in human tenascin-X have also been reported in connection with the hyperextensibility
of the skin and joints [54]. Although none of the Bearded Collies included in this study
carried either of those mutations mentioned above, and none displayed any systemic skin
or joint abnormalities, the finding does support a role for TNXB in canine integument
lending further support for a potential role of TNXB in SLO.
In addition to TNXB, five other protein-coding genes harbored variants considered as
possible candidate variants in SLO disease development: TCF19, LTB, GPSM3, HLA-DQB2,
and FGD2. Out of these, the HLA-DQB2 variant could be considered the strongest candidate
for SLO, given that the variant is in exon 2 of the gene, which encodes the binding site of the
DLA molecule produced [55]. MHC molecules are instrumental to central tolerance and,
through their binding sites, participate in thymic T-cell development leading to deletion
of potentially autoreactive T cells [56]. Certain MHC class II haplotypes are thought to
contribute to autoimmunity by failing to eliminate autoreactive T cells, allowing them to
escape thymic selection [56,57]. Sequencing of the exon 2 of each of the three polymorphic
DLA class II genes (major histocompatibility complex, class II, DR beta 1, DLA-DRB1;
major histocompatibility complex, class II, DQ alpha 1, DLA-DQA1; and HLA-DQB2) is
used to determine three-locus DLA class II haplotypes [8,58], and the variant of interest
identified in this study is shared by four DLA class II haplotypes seen in Bearded Collies,
including the two very similar haplotypes that were associated with increased risk for
SLO [8]. This would explain the lower OR seen with this variant and why risk for disease
is better captured by the presence of one or two three-locus DLA class II risk haplotypes for
SLO, which remains more informative of disease risk in Bearded Collies than the individual
HLA-DQB2 variant (rs851008370).
Among the remaining variants of interest, the one in LTB (rs852946032) might be
considered the second strongest candidate variant given its LTB gene function. LTB encodes
the lymphotoxin β protein, which is a member of the tumor necrosis factor superfamily
and critical to immune system development [59]. The gene is known to be important
in regulating innate and adaptive immune responses [60] and has been found to be up-
regulated in a group of human inflammatory diseases, thus suggesting that LTB may
play a role in perpetuating inflammation [61]. Moreover, LTB deficiency has been shown
to prevent autoimmunity in non-obese diabetic mice, allergic encephalomyelitis, and
experimental murine colitis models [59]. However, the LTB variant identified in this study
also had a low OR, and a large number of control dogs was found to be homozygous for
the non-reference and potentially deleterious allele. Canine LTB has two transcripts, one
resulting in a much smaller protein than the other. The observed variant associated with
SLO in the Bearded Collie causes a glycine at position 52 of the protein to be substituted by
glutamic acid; this corresponds to the first fourth of the larger transcript and the last third
of the smaller transcript. Although the variant affects both transcripts, Provean predicted it
to be neutral in the larger transcript and deleterious in the smaller one. The C-terminal end
of the protein, which is likely to be exposed on the cell surface and possibly involved in
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receptor binding, is the most conserved region of the protein [62], thus supporting Provean
predictions. While it is possible that there is a transcript dosage effect influencing SLO
expression, with the predicted deleterious transcript reducing the functionality of the LTB
protein, it is also possible that the larger transcript is able to compensate for the smaller
transcript and that the variant observed in LTB would not be sufficient to induce disease in
the Bearded Collies.
The last gene with a clear involvement in immune function is FGD2, which is expressed
in leukocytes, B cells, macrophages, and dendritic cells, and plays a role in immune system
signaling and vesicle trafficking [63]. While its function in the immune system could make
it a candidate gene for SLO, the associated variant identified in this gene also had one of
the lowest ORs, with cases and controls presenting similar proportions of homozygous
non-reference and heterozygous genotypes. While it may still be contributing to SLO
susceptibility in combination with other variants, there is no clear evidence of this from
our findings.
Frameshift variants can have severe consequences on the resulting protein [48], es-
pecially when they occur towards the beginning of the coding sequence. This is the case
for the variant in GPSM3 (rs851873877), which causes a frameshift starting at the third
amino acid of the protein, introducing a premature stop codon and thereby terminating
the protein sequence at only 30 amino acids. As expected, the variant also presented with
the strongest OR and LD along with the TNXB variants, given their physical proximity on
the chromosome. Human GWAS studies have pointed to an inverse correlation between
GPSM3 and autoimmune diseases, demonstrating that polymorphisms in this gene were
associated with the decreased incidence of immune-mediated diseases such as rheumatoid
arthritis and systemic lupus erythematosus (SLE) [64]. While clearly causing significant
changes to the resulting protein, the identified variant only affects one of the known canine
GPSM3 transcripts and is intronic to the other two. It is therefore possible that the other
transcripts compensate for the affected one. Combined with the strong LD observed with
other variants identified in this study, it is unclear whether this variant could have a role in
SLO disease development or is simply linked to the true causative variant(s).
The two frameshift variants in TCF19 (novel variants: p.Gln114fs and p.Trp164fs),
leading to significant amino acid changes in the first fourth of the protein as well as a
premature stop codon, were strongly associated with SLO and also in strong LD with the
TNXB, LTB, and GPSM3 variants. The TCF19 gene encodes a transcription factor involved
in regulating cell proliferation and differentiation and has been implicated in type 1 diabetes
where it appears to act as a regulator of β-cell mass in the pancreas [65,66]. Despite its
association with another organ-specific autoimmune disorder, there is no other evidence in
the literature to connect this gene’s function to SLO development. Finally, although the
variants in C12H6orf15 and ENSCAFG00000041540 (defined as a pseudogene in Ensembl)
had a significant association with SLO, there is little known about these genes and how
they may predispose to SLO. Furthermore, the high LD evident between these variants
and variants located in stronger candidate genes that have a clear potential involvement in
disease development, reduce the likelihood of their contribution to SLO risk.
Despite a definite association between CFA17 and SLO [11], no variants of interest
were identified throughout the associated region. A separate investigation of variants
within a potential candidate gene adjacent to the associated region also failed to reveal any
variants significantly segregating with disease status. The region of association on CFA17
is relatively gene-poor, with few regulatory motifs. It is possible that the region may harbor
regulatory elements that could influence the expression of the adjacent REG3A gene, but
no such variants were obvious.
While conferring an advantage to association mapping in the dog [13], long stretches
of LD can make fine mapping of true causative variants more challenging, as exemplified
by the present study. A significant challenge in the search for WGS variants that increase
risk susceptibility for SLO is that the entire region of association on CFA12 is in strong LD.
Genotype imputation in a larger number of unrelated cases and controls allowed five of
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the variants identified in WGS to be discarded from further consideration. As previously
reported, Bearded Collies carry two types of DLA class II haplotypes that are strongly
associated with SLO disease development [8,11]. While the involvement of TNXB seems
plausible, given its ubiquitous expression in the skin and the presence of a non-reference
allele at each of the TNXB variant locations, the variants were fully linked to the presence
of DLA class II risk haplotypes for SLO. In fact, the three TNXB variants were also in
strong LD, with almost all of the other variants of interest identified, making it difficult to
determine which variant, or combination of variants, may play a role in SLO susceptibility
in Bearded Collies. After evaluating the role of each of the variants in the candidate genes
and assessing their potential involvement based upon protein function, a logical conclusion
is that the risk susceptibility observed likely reflects the DLA class II haplotypes. The
presence of variants in the candidate genes are inextricably linked to the presence of the
DLA class II risk haplotypes, creating one very large risk haplotype encompassing many
genes. Given the genetic structure of the region, successfully isolating the different variants
to assess their effects on SLO disease development may not be possible even if additional
dogs were sequenced at the whole genome level. Since the GWAS-associated region on
CFA12 was similar for Bearded Collies and Gordon Setters, sequencing of SLO and healthy
dogs from other SLO-affected breeds such as the Gordon Setter may help clarify which
of the variants on CFA12 are associated with disease and which ones are simply in LD
with the causative variants, assuming the genetic cause of SLO is the same across dog
breeds and the variants are not in LD in different breeds. It should also be noted that the
methodology employed in the current study focused on variants with a high or moderate
SnpEff-predicted impact. Variants in introns and untranslated regions of genes as well as
intergenic variants, which are considered by SnpEff to have only modifier effects, were
excluded from analysis by our filtering process. However, such variants may play a role in
disease development through the regulation of gene expression, and further exploration
of such variants within the associated region could reveal additional associations with
disease. Alternatively, although an invasive procedure, a biopsy and the subsequent gene
expression profiling of the nail beds of SLO affected and unaffected dogs might shed light
on which of these genes are truly associated with the condition.
Despite the limitations, the present study was able to refine the associated region
on CFA12, identifying several genetic variants in potential candidate genes that have
predicted damaging effects and are strongly associated with SLO disease expression in the
Bearded Collies. In terms of biological function, the DLA class II genes may still be the
most probable causal genes in SLO, although a combination of the DLA class II haplotypes
with one or more of the variants identified in this study cannot be excluded. Given that the
potentially damaging variants and DLA class II risk haplotypes for SLO are quite abundant
in the Bearded Collie population, strong selection against these alleles could result in a
significant loss of genetic diversity to the breed. Nonetheless, the variants and DLA class II
risk haplotypes are strongly predictive of SLO status in this breed and, if used judiciously,
their application to inform breeding decisions may prove helpful to reduce the incidence
of SLO in the breed population.
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